Omixon will be attending American Society of Bone and Marrow Transplantation Salt Lake City, 13-17 February 2013

20/01/2013

The American Society for Blood and Marrow Transplantation is an international professional association that promotes the advancement of the blood and marrow transplantation field. ASBMT members are both in clinical practice, in research, and health professionals. From its beginning, ASBMT activities have been representing the interests of transplant clinicians and...

Omixon will attend Molecular Medicine TriConference San Francisco, 11-15 Feb 2013

15/01/2013

The Molecular Med Tri-Con is a four day conference which will see more than 3,000 attendees participating in interactive lectures, discussions, and various receptions as a way to facilitate networking opportunities and hearing differing views and perspectives . It includes 2 partnering forums, symposia, short courses, and core programs that...

Next-Generation Sequencing Technologies: Video Presentation

14/01/2013

Elaine R Mardis is a Professor of Genetics at Washington University and Co-Director of The Genome Institute. She recently gave a presentation about next generation sequencing technologies.

Next Generation Sequencing in Hematology

11/01/2013

The Top 3 specialties in which doctors spend the most hours online per week is hematology, endocrinology and OB/GYN. Hematologists are generally interested in HLA, and as Omixon Target HLA offers the highest possible HLA typing precision, we keep an eye on the medical literature and seek opportunities through which...

Omixon could be “The Most Promising Company” of 2013

10/01/2013

Omixon is presenting and exhibiting at the upcoming Personalized Medicine World Conference in Mountain View, from 28-29th Jan 2013. We are a nominee for the “The Most Promising Company” award. Emerging companies that develop solutions for the next generation of personalized medicine platforms are invited to the competition.